Avobenzone

Summary

Avobenzone (CHEMBL1200522) is an approved small molecule; indicated across 3 conditions including sunburn and skin neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 310.4 Da · C20H22O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200522
Name	Avobenzone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	51040
Molecular formula	C20H22O3
Molecular weight	310.4
InChIKey	XNEFYCZVKIDDMS-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)OC

IUPAC name: 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione

Also known as: Avobenzona, Avobenzone, Avobenzone component of anthelios sx, Avobenzone component of capital soleil, Avobenzone component of shade uvaguard, Butyl methoxydibenzoylmethane, Escalol 517, Eusolex 9020, Neoheliopan 357, NSC-758680, Parsol 1789, SID26748930

Patent coverage: 11,288 distinct patent families (34,067 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, ATP-dependent DNA helicase Q1, Polyunsaturated fatty acid lipoxygenase ALOX15, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1, 3-hydroxyacyl-CoA dehydrogenase type-2, DNA repair nuclease/redox regulator APEX1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.15	Potency	70.8	nM	CHEMBL_ACT_3622481
APEX1	5.1	Potency	7943	nM	CHEMBL_ACT_3798702

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sunburn	4	MONDO:0005326	EFO:0003958
skin neoplasm	4	MONDO:0002531	MONDO:0002898

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05865431	Not specified	COMPLETED	Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).